23 studies found for:    Open Studies | copd | United States, North Carolina
Show Display Options
Rank Status Study
1 Recruiting Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
Conditions: COPD;   Chronic Obstructive Pulmonary Disease;   Moderate to Very Severe COPD
Interventions: Drug: Aclidinium Bromide;   Drug: Placebo
2 Recruiting Efficacy and Safety Study of QVA149 in COPD Patients
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149;   Drug: Umeclidinium/vilanterol;   Drug: Placebo (umeclidinium/vilanterol);   Drug: Placebo (QVA149)
3 Recruiting Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149;   Drug: Umeclidinium/vilanterol;   Drug: Placebo (umeclidinium/vilanterol );   Drug: Placebo (QVA149)
4 Recruiting Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
Condition: COPD
Interventions: Drug: BGF MDI 320/14.4/9.6 μg;   Drug: GFF MDI 14.4/9.6 μg;   Drug: BGF MDI 160/14.4/9.6 μg;   Drug: BFF MDI 320/9.6 μg
5 Recruiting Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Placebo
6 Recruiting Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Benralizumab Arm C;   Drug: Placebo
7 Recruiting Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Condition: COPD
Interventions: Drug: BGF MDI (PT010) 320/14.4/9.6 μg;   Drug: GFF MDI (PT003) 14.4/9.6 μg;   Drug: BFF MDI (PT009) 320/9.6 μg
8 Recruiting A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
Condition: COPD
Interventions: Drug: BGF MDI 320/14.4/9.6 μg;   Drug: GFF MDI (PT003) 14.4/9.6 μg;   Drug: BFF MDI (PT009) 320/9.6 μg;   Drug: Symbicort® Turbuhaler® (TBH) Inhalation Powder
9 Recruiting Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
Condition: COPD
Interventions: Drug: GFF MDI (PT003);   Drug: FF MDI (PT005);   Drug: GP MDI (PT001);   Drug: Placebo MDI
10 Recruiting AMPLIFY - D6571C00001 Duaklir USA Phase III Study
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg);   Drug: Aclidinium bromide 400 μg (AB 400 μg);   Drug: Formoterol fumarate 12 μg (FF 12 μg);   Drug: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg;   Drug: Tiotropium 18 μg (TIO 18 μg);   Drug: Placebo to TIO 18 μg
11 Not yet recruiting A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD.
Condition: Chronic Obstructive Pulmonary Disorder
Interventions: Drug: BFF MDI 320/9.6 μg;   Drug: BFF MDI 160/9.6 μg;   Drug: FF MDI 9.6 μg;   Drug: BD MDI 320 μg
12 Recruiting Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb).
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Formoterol fumarate (6 μg);   Drug: Formoterol furmarate (20 μg);   Drug: Placebo for formoterol fumarate;   Drug: Formoterol fumarate (12 μg);   Drug: Formoterol fumarate (40 μg)
13 Recruiting A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate (FF);   Drug: vilanterol (VI);   Drug: umeclidinium bromide (UMEC)
14 Not yet recruiting A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period (Sophos)
Condition: Chronic Obstructive Pulmonary Disorder
Interventions: Drug: BFF MDI (PT009) 320/9.6 μg;   Drug: BFF MDI (PT009) 160/9.6 μg;   Drug: FF MDI (PT005) 9.6 μg
15 Recruiting Phase IV O2 Consumption Study in COPD Patients
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Budesonide 160 mcg and formoterol fumarate dehydrate 4.5 mcg Inhalation aerosol;   Drug: Matching Placebo pMDI 160/4.5 μg
16 Recruiting A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
Condition: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Drug: QBW251;   Drug: Placebo
17 Unknown  Evaluation of FeNO During and Following Acute COPD Exacerbation
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Device: NIOX MINO®
18 Not yet recruiting Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)
Conditions: COPD;   Anxiety;   Depression;   Stress
Interventions: Drug: Sertraline;   Drug: Placebo
19 Not yet recruiting The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
Conditions: Chronic Obstructive Pulmonary Disease (COPD);   Emphysema;   Chronic Bronchitis
Intervention:
20 Recruiting Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: Adipose Derived Stem Cell (ADSC) Therapy

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Indicates status has not been verified in more than two years